Drug Approval | May 24, 2022
Cadila Pharma launches Belmore to treat uncontrolled LDL-cholesterol
Belmore, the brand name of Bempedoic acid, is a novel drug for the treatment of high LDL-cholesterol.
Belmore, the brand name of Bempedoic acid, is a novel drug for the treatment of high LDL-cholesterol.
Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
Bempedoic Acid administered as a 180-mg dose, is approved by the USFDA and European Union for the treatment of hypercholesterolemia
To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
The workshop was organized by the Department of Urology as a first step to enabling government medical colleges in Rajasthan to offer the latest surgical technology
The plant is expected to start commercial operations from Q4FY24
Essent continues to broaden its highly characterized, low passage primary cell catalog
The science leader comes with a rich experience in the employment testing industry
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
Subscribe To Our Newsletter & Stay Updated
